Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA): Implementation of PsOWellTM in PsA
This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).
• Population: Patients with Psoriatic Arthritis
‣ Age 18-89.
⁃ Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10).
⁃ Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit).
⁃ Meet CASPAR criteria.
⁃ Provision of signed and dated informed consent form.
⁃ Willingness to comply with all study procedures and availability for duration of the study.
⁃ Has access to a mobile phone or other mobile device.